



# PARENTERAL DRUGS (INDIA) LTD.



## Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September 2015

M5000712ID

PART - I		(Rs in Lacs)					
Sr. No.	Particulars	Three ended 30/09/2015 Unaudited	Preceding three ended 30/06/2015 Unaudited	Corresponding three ended 30/09/2014 Unaudited	Half Year ended 30/09/2015 Unaudited	Corresponding Half Year ended 30/09/2014 Unaudited	Previous year ended 31/03/2015 Audited
1	<b>Income from Operation</b>						
	(a) Net Sales/Income from Operations (Net of Excise Duty)	5869.48	5094.76	4746.31	10984.24	10034.24	17589.31
	(b) Other Operating Income	12.85	92.57	2.05	105.42	4.89	69.68
	<b>Total Income From Operation (Net)</b>	<b>5882.33</b>	<b>5187.33</b>	<b>4748.36</b>	<b>11069.66</b>	<b>10,039.13</b>	<b>17658.99</b>
2	<b>Expenditure</b>						
	a) Consumption of Material Consumed	973.49	3120.41	2685.02	4093.90	5500.91	8689.93
	b) Purchase of Stock in Trade	3305.18			3305.18		
	c) Change in Inventories of Finished Goods, Work in Progress and Stock in trade	179.00	(104.27)	-368.81	74.73	-174.31	(784.83)
	d) Employee Benefit Expenses	209.98	425.14	444.48	635.12	908.05	1844.36
	e) Depreciation and Amortisation Expenses	525.88	525.88	442.12	1051.76	884.24	2385.06
	f) Other Expenditure ( Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately)	703.23	1218.48	1715.23	1921.71	3334.76	6568.73
	<b>Total Expenses</b>	<b>5896.76</b>	<b>5185.64</b>	<b>4918.04</b>	<b>11082.40</b>	<b>10453.65</b>	<b>18703.25</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(14.43)</b>	<b>1.69</b>	<b>(169.68)</b>	<b>(12.74)</b>	<b>(414.53)</b>	<b>(1044.26)</b>
4	Other Income						
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items</b>	<b>(14.43)</b>	<b>1.69</b>	<b>(169.68)</b>	<b>(12.74)</b>	<b>(414.53)</b>	<b>(1044.26)</b>
6	Finance costs	1055.14	1438.76	1467.93	2493.90	2868.96	5917.34
7	Profit/(Loss) from ordinary activities after finance cost but before Exceptional items	(1,069.57)	(1437.07)	(1,637.61)	(2,506.64)	(3,303.49)	(6961.60)
8	Exceptional items						(40.72)
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(1,069.57)	(1437.07)	(1,637.61)	(2,506.64)	(3,303.49)	(7002.32)
10	Tax Expenses	0.00	6.01	91.89	6.01	183.78	(1593.84)
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,069.57)	(1443.08)	(1,729.50)	(2,512.65)	(3,487.27)	(5408.48)
12	Extraordinary items (net of tax expense)		0.00				0.00
13	<b>Net Profit / (Loss) for the period (11 + 12)</b>	<b>(1,069.57)</b>	<b>(1443.08)</b>	<b>(1,729.50)</b>	<b>(2,512.65)</b>	<b>(3,487.27)</b>	<b>(5408.48)</b>
14	Share of profit / (loss) of associates*						
15	Minority interest *						
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *</b>	<b>(1,069.57)</b>	<b>(1443.08)</b>	<b>(1,729.50)</b>	<b>(2,512.65)</b>	<b>(3,487.27)</b>	<b>(5408.48)</b>
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63	2981.63	2981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						6418.93
19 i	<b>Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):</b>						
	(a) Basic	(3.59)	(4.84)	(5.80)	(8.43)	(11.70)	(18.14)
	(b) Diluted	(3.59)	(4.84)	(5.80)	(8.43)	(11.70)	(18.14)
19 ii	<b>Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):</b>						
	(a) Basic	(3.59)	(4.84)	(5.80)	(8.43)	(11.70)	(18.14)
	(b) Diluted	(3.59)	(4.84)	(5.80)	(8.43)	(11.70)	(18.14)

\* Applicable in the case of consolidated results.


Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details in the

Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA  
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA  
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl\_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481



**PDPPL PARENTERAL DRUGS  
(INDIA) LTD.**



**NOTES :**

- 1 The above results were reviewed by statutory auditors and audit committee of the company on 9 th November 2015 and approved by Board of Directors in their meeting held on 9th November 2015
- 2 At the moment the company is having only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17) as the business under proposed real estate segment is yet to commence.
- 3 Company has revalued land situated at village Asrawad , Indore and reserve and surplus and fixed assets includes revaluation reserve of Rs.262.18 crores.
- 4 The figures for previous year/period have been regrouped/rearranged wherever found necessary.
- 5 The standalone financial results of the company are available on the website of the company i.e. [www.pdindia.com](http://www.pdindia.com) and on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).

Place: Indore  
Date: 9th November 2015

For and on behalf of Board of Directors

A handwritten signature in black ink, appearing to read 'Vinod Kumar Gupta', is written over a circular stamp.

Vinod Kumar Gupta  
Whole time Director



Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA  
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: [pdpl@pdindia.com](mailto:pdpl@pdindia.com)

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA  
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: [pdpl\\_mumbai@pdindia.com](mailto:pdpl_mumbai@pdindia.com) -----

-----  
Website: [www.pdindia.com](http://www.pdindia.com), CIN: L99999MH1983PLC126481

# PDPL PARENTERAL DRUGS (INDIA) LTD.



M5000712ID

## Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September 2015

PART - I							
Sr. No.	Particulars	Three months ended 30/09/2015 Unaudited	Preceding three months ended 30/06/2015 Unaudited	Corresponding three months ended 30/09/2014 Unaudited	Half Year ended 30/09/2015 Unaudited	Corresponding Half Year ended 30/09/2014 Unaudited	(Rs in Lacs) Previous year ended 31/03/2015 Audited
1	<b>Income from Operation</b>						
	(a) Net Sales/Income from Operations (Net of Excise Duty)	7998.16	8804.81	6767.99	16802.97	14479.27	26266.92
	(b) Other Operating Income	29.53	94.65	3.04	124.18	7.54	96.36
	<b>Total Income From Operation (Net)</b>	<b>8027.69</b>	<b>8899.46</b>	<b>6771.04</b>	<b>16927.15</b>	<b>14486.81</b>	<b>26363.28</b>
2	<b>Expenditure</b>						
	a) Cost of Material Consumed	1914.98	4336.09	4402.15	6251.07	8747.95	14936.95
	b) Purchase of Stock In Trade	3739.94	859.40		4599.34		0.00
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	270.78	297.12	-843.81	567.90	-770.24	(2292.58)
	d) Employee Benefit Expenses	324.58	557.67	540.62	882.25	1137.13	2358.09
	e) Depreciation and Amortisation Expenses	676.14	676.14	574.76	1352.28	1149.66	3097.90
	f) Other Expenditure ( Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately)	1161.79	2059.95	2348.22	3221.74	4777.40	9833.07
	<b>Total Expenses</b>	<b>8088.21</b>	<b>8786.37</b>	<b>7021.94</b>	<b>16874.58</b>	<b>15041.90</b>	<b>27933.43</b>
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(60.52)	113.09	(250.91)	52.57	(555.09)	(1570.15)
4	Other income						
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(60.52)	113.09	(250.91)	52.57	(555.09)	(1570.15)
6	Finance costs	1341.40	1777.84	1715.86	3119.24	3368.24	7025.16
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional items (5-6)	(1,401.92)	(1,664.75)	(1,966.77)	(3,066.67)	(3,923.33)	(8595.31)
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	40.72
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(1,401.92)	(1,664.75)	(1,966.77)	(3,066.67)	(3,923.33)	(8636.03)
10	Tax Expenses	52.08	58.09	91.89	110.17	183.78	(1872.63)
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,454.00)	(1,722.84)	(2,058.66)	(3,176.84)	(4,107.11)	(6763.40)
12	Extraordinary items (net of tax expense Lakhs)						
13	Net Profit / (Loss) for the period (11 + 12)	(1,454.00)	(1,722.84)	(2,058.66)	(3,176.84)	(4,107.11)	(6763.40)
14	Share of profit / (loss) of associates*						
15	Minority interest *						
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1,454.00)	(1,722.84)	(2,058.66)	(3,176.84)	(4,107.11)	(6763.40)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63	2981.63	2981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						8070.76
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(4.88)	(5.78)	(6.90)	(10.65)	(13.77)	(22.68)
	(b) Diluted	(4.88)	(5.78)	(6.90)	(10.65)	(13.77)	(22.68)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(4.88)	(5.78)	(6.90)	(10.65)	(13.77)	(22.68)
	(b) Diluted	(4.88)	(5.78)	(6.90)	(10.65)	(13.77)	(22.68)

Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof

Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA

Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA

Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl\_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481





**PART -II**

<b>A PARTICULARS OF SHAREHOLDING</b>						
<b>1</b>	<b>Public Shareholding</b>					
	-Number of Shares	7967057	7967057	7967057	7967057	7967057
	-Percentage of shareholding	26.72%	26.72%	26.72%	26.72%	26.72%
<b>2</b>	<b>Promoters and Promoter Group Shareholding **</b>					
	<b>a) Pledged/Encumbered</b>					
	-Number of shares	21,849,243	21,849,243	15076441	21,849,243	15076441
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	69.00%	100.00%	69.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	73.28%	73.28%	50.56%	73.28%	50.56%
	<b>b) Non-encumbered</b>					
	-Number of shares			6772802		6772802
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)			31.00%		31.00%
	-Percentage of Shares (as a % of the total share capital of the Company)			22.72%		22.72%
<b>B</b>	<b>Detail of Investor Compliant</b>			<b>3 months ended (30.09.2015)</b>		
	Pending at the beginning of the quarter					0
	Received during the quarter					0
	Disposed of during the quarter					0
	Remaining unresolved at the end of the quarter					0

**Statement of Assets and Liabilities**

Sr. No.	Particulars	30.09.2015	31.03.2015
		Unaudited	Audited
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Shareholders' funds</b>		
	(a) Share Capital	4770.42	4520.42
	(b) Reserves and Surplus	33906.28	8189.81
	<b>Sub-total - Shareholders' funds</b>	<b>38676.70</b>	<b>12710.23</b>
<b>2</b>	<b>Share application money pending allotment</b>	0.00	0.00
<b>3</b>	<b>Minority interest *</b>	65.04	65.04
<b>4</b>	<b>Non-current liabilities</b>		
	(a) Long-term borrowings	47833.90	41228.73
	(b) Deferred tax liabilities (net)	1583.91	1473.75
	<b>Sub-total - Non-current liabilities</b>	<b>49417.81</b>	<b>42702.48</b>
<b>5</b>	<b>Current liabilities</b>		
	(a) Short-term borrowings	10173.75	10153.97
	(b) Trade payables	8726.65	6124.26
	(c) Other current liabilities	7210.77	5830.69
	(d) Short-term provisions	869.08	868.43
	<b>Sub-total - Current liabilities</b>	<b>26980.25</b>	<b>22977.35</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>115139.80</b>	<b>78455.10</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Fixed assets	76938.27	41371.21
	(b) Goodwill on consolidation *	12870.65	12870.65
	(c) Non-current investments	1.10	1.10
	(d) Long-term loans and advances	539.96	639.27
	(e) Other non-current assets	86.81	86.80
	<b>Sub-total - Non-current assets</b>	<b>90436.79</b>	<b>54969.03</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	8645.71	8027.25
	(b) Trade receivables	14256.62	13936.67
	(c) Cash and cash equivalents	618.73	308.36
	(d) Short-term loans and advances	758.54	690.60
	(e) Other current assets	423.41	523.18
	<b>Sub-total - Current assets</b>	<b>24703.01</b>	<b>23486.06</b>
	<b>TOTAL - ASSETS</b>	<b>115139.80</b>	<b>78455.10</b>



Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA  
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA  
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl\_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481

# PDPPL PARENTERAL DRUGS (INDIA) LTD.



**NOTES :**

- 1 The above results were reviewed by statutory auditors and audit committee of the company on 9th November 2015 and approved by Board of Directors in their meeting held on 9th November 2015
  - 2 The unaudited financial results of the subsidiary companies have been consolidated.
  - 3 At the moment the company is having only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17) as the business under proposed real estate segment is yet to commence.
  - 4 Parent Company has revalued land situated at village Asrawad, Indore and reserve and surplus and fixed assets includes revaluation reserve of Rs.262.18 crores.
  - 5 The figures for previous year/period have been regrouped/rearranged wherever found necessary.
  - 6 The consolidated financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- The key standalone financial results are given below:

Sr. No.	Particulars	Quarter Ended		Half Year Ended		Prev. Year Ended	
		Unaudited 30.09.2015	Unaudited 30.06.2015	Unaudited 30.09.2014	Unaudited 30.09.2015	Unaudited 30.09.2014	Audited 31.03.2015
1	Income from operations & other income	5,882.33	5,187.33	4,748.36	11,069.66	10,039.13	17,658.99
2	Profit/Loss before tax	(1,069.57)	(1,437.07)	(1,637.61)	(2,506.64)	(3,303.49)	(7,002.32)
3	Profit/Loss after tax	(1,069.57)	(1,443.08)	(1,729.50)	(2,512.65)	(3,487.27)	(5,408.48)

For and on behalf of Board of Directors

Place: Indore  
Date: 9th November 2015



Vinod Kumar Gupta  
Whole time Director

Corporate Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing, Indore-452 001 (M.P.) INDIA  
Tel.: (0731) 6652001, 6652002, 6652003, 4092000; Fax: (0731) 2401052; E-mail: pdpl@pdindia.com

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) INDIA  
Tel.: (022) 61725900, 61725901; Fax: (022) 26333763; E-mail: pdpl\_mumbai@pdindia.com

Website: www.pdindia.com, CIN: L99999MH1983PLC126481

**T.N. UNNI & Co.**  
Chartered Accountants

402, Alankar Point,  
4-A, Rajgarh Kothi,  
Geeta Bhawan Square,  
A.B.Road,  
Indore- 452001

**Review Report to  
National Stock Exchange of India Limited/  
Bombay Stock Exchange Limited**

We have reviewed the accompanying statement of unaudited financial results of M/s. Parenteral Drugs (India) Limited for the period ended 30<sup>th</sup> September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: *INDORE*

Date: *9 NOV 2015*

**For T.N. UNNI & Co.  
Chartered Accountants**



**T.N. Unni  
(Partner)  
M. No. 14520  
F.R.N. 004890C**